SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gemini who wrote (1087)1/19/2001 9:06:17 PM
From: scaram(o)uche  Read Replies (1) of 1298
 
Cell Genesys executed a license agreement with Hoechst Marion Roussel, now
Aventis Pharmaceuticals, in February 1997 for gene-activated EPO and a
second undisclosed protein. The agreement provides for up to $26
million in milestone payments and fees, in addition to any royalties
on future sales of these two potential gene-activated protein
products. As of February 2000, Cell Genesys had received over $15
million under this license agreement, including a milestone payment
for the 1998 initiation of a Phase III clinical trial for gene-
activated EPO, which Hoechst Marion Roussel is developing in
collaboration with Transkaryotic Therapies, Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News